Arestat™ Protein Stabilisation Technology
Arestat™ comprises two fundamentally different aspects of our platform stabilisation technology – Arestat-T™ and Arestat-R™. Both utilise excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability.
Both are available for licensing for therapeutic proteins, vaccines, medial devices and diagnostics.
Partnered Projects
Arecor’s objective is to develop stable advanced formulations through the application of Arestat™ that are commercially relevant for their industrial partners. Arecor therefore seeks partners with therapeutic or diagnostic candidates that are : (i) difficult to stabilise through conventional formulation methods or (ii) which could benefit from a change in presentation such as a 'lyophilised powder in vials' to 'ready-to-use liquid in pre-filled syringes' or (iii) an aqueous solution with instructions to 'store refrigerated at 2-8°C' being available as 'store at room temperature'.
Our aim is to address the stability issues which may seem insurmountable and bring stabilised products into clinical development as early as possible. We understand that every month lost in development is a month of revenue lost post marketing authorisation.
Arecor is seeking partners interested in the development of new or off-patent (or near patent expiry) biologics for whom they can develop advanced formulations with superior stability profiles. Examples of some partnered projects are listed below:

ExampleRoute of AdministrationPresentationObjective
Biodefense vaccineSubcutaneous or IMLiquidSignificantly improved shelf life
Clotting factorsInfusion i.v.LiquidStable aqueous preparation to replace powder for reconstitution
Follow-on biologicSubcutaneousLiquidPatent extension with improved formulation
High conc mAbsSubcutaneousLiquidImproved delivery
High conc. hormoneSubcutaneousLiquidMore convenient presentation stable at room temperature
In-dwelling sensorSubcutaneousDryTerminal sterilization; stable at 37°C (body temperature)
Polysacchride vaccineSubcutaneousLiquidStable outside the cold chain at 37°C
Protein DepotSubcutaneousDryTerminal sterilization; depot stable at 37°C (body temperature)
Single Chain AntibodyOphthalmicLiquidStable at 2-8°C with <4% aggregation
Therapeutic enzymeInfusionLiquidStable aqueous preparation to replace powder for reconstitution
Topical ProteinPatchLiquidStable at 37°C (body temperature)
Virus-like particleSubcutaneousLiquidStable outside the cold chain at 37°C

To explore partnering opportunities contact us at info@arecor.com or use the Enquiry Form